Latest biopharmaceutical Stories

HERZLIYA, Israel, September 24, 2012 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. ("XTL") today announced that InterCure Ltd. ("InterCure"), which is approximately 45.4% (50.79% on a fully diluted basis) held by XTL, signed a strategic service agreement with a private company ("the Marketing Company") wholly owned by Mr. Shay Ben Yitzhak and Mr. Avner Yassur. Ben Yitzhak and Yassur, who are behind several of the most successful online marketing ventures, are now entering...

JUPITER, Fla., Sept. 24, 2012 /PRNewswire/ -- Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced today that it has been issued U.S. Patent No. 8,268,585 entitled, "Transformation System in the Field of Filamentous Fungal Hosts" by the United States Patent and...

BRIDGEWATER, N.J., Sept. 24, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced the appointment of John P. Hamill as Senior Vice President & Chief Financial Officer effective today. Mr. Hamill brings over 25 years of global financial and administrative operational experience to Savient with a specialized background in pharmaceutical service industry. Mr. Hamill will be responsible for all financial and accounting functions of the Company and will...

TARRYTOWN, N.Y., Sept. 21, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that Science magazine has ranked Regeneron as the #1 employer in the global biopharmaceutical industry in the journal's annual Top Employers Survey. "This recognition by Science as the most respected company to work for in the biopharmaceutical industry is very satisfying for all of us at Regeneron," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive...

BELLEVILLE, ON, Sept. 20, 2012 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that one of its equine products - HIPPIRON(TM )1000 - has been counterfeited, and was discovered being sold via an Internet website. Regulatory authorities and veterinarian customers have been advised of this situation, along with the elements of the counterfeited product that clearly distinguish it...

Gallus BioPharmaceuticals, LLC (Gallus)—a leading provider of contract services to biopharmaceutical companies — announced today a collaboration agreement with Roslin Cells Ltd. (Roslin Cells), based in Edinburgh, Scotland, to develop and supply clinical and commercial cell therapy products. (PRWEB) September 18, 2012 In this partnership, Gallus will provide process development, clinical and commercial supply for cell therapy-based biopharmaceutical products to Roslin Cells’...

CAMBRIDGE, Mass., Sept. 18, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) announced today the appointment of two new independent Directors to the Company's Board of Directors. Scott A. Canute and Gino Santini provide Inspiration access to unparalleled expertise in biopharmaceuticals manufacturing and business development as the company moves toward commercialization of its portfolio of products currently in late-stage development for hemophilia. The new...

CAMBRIDGE, England, September 18, 2012 /PRNewswire/ -- First human antibody strain from its advanced discovery platform Kymab, a monoclonal antibody biopharmaceutical company, announced today the launch of Kymouse HK, the first strain from the innovative Kymouse(TM) antibody discovery platform, which enables rapid discovery of high affinity antibody drug candidates. Kymouse HK is a transgenic mouse that has been designed to produce a diverse repertoire...

CAMBRIDGE, Mass., Sept. 13, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc., an emerging biopharmaceutical company developing new treatment options for people with hemophilia, today announced that John P. Butler, Chief Executive Officer, will present at the UBS Global Life Sciences Conference on Thursday, September 20, 2012. The presentation will take place at 4:00 p.m. ET at the Grand Hyatt Hotel in New York. About Inspiration BiopharmaceuticalsAs the only...

LYNBROOK, N.Y., Sept. 13, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced that Tom Wegman, President of BioSpecifics, will present at the upcoming UBS Global Life Sciences Conference at 1:30 pm EDT on Thursday, September 20, 2012 in New York, NY. The live webcast of this presentation may be accessed...